Early recognition of POEMS syndrome: what is the role of clinical neurophysiology?
- Okatsu Neurology and Rehabilitation Hospital, 3-95 Masagohonpachi, Kagoshima, Japan
- Correspondence to Dr Kimiyoshi Arimura, Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medicine, 8351 Sakuragaoka, Kagoshima 9.80852e+006, Japan;
Contributors KA is the sole contributor to this commentary.
- Received 9 February 2012
- Revised 17 February 2012
- Accepted 18 February 2012
POEMS syndrome (also known as Crow–Fukase syndrome) is a serious systemic disease characterised by polyneuropathy, anasarca, skin lesions and associated with ostoclastic bone lesions and with M-proteinemia. The diagnosis of POEMS syndrome is made robust by finding increased serum/plasma vascular endothelial growth factor (VEGF) in addition to the combination of the above mentioned characteristic manifestations.1 In fact, the recognition of POEMS syndrome has been enunciated by recent diagnostic guidelines from the western and Asian countries. From our end, a second nationwide survey of POEMS syndrome was conducted in Japan in 2004. The estimated number of affected individuals all over Japan was calculated …